¡ã (Ãâó: pixabay)

Since COVID-19 swept the world, interest in medical devices has been increasing, and 'Neptune Korea', which has started a safer and smarter blood collection needle research and development, is drawing attention.

Neptune Korea is researching and developing a solution to improve problems such as pain that existing blood collection needles have, and to block secondary infection by reuse. The global smart healthcare market has grown by more than 20% annually from about $96 billion since 2016 and is expected to reach about $26 billion this year. In particular, the global smart healthcare product market for devices is expected to grow at an annual average of 8% from about $31.7 billion in 2016 to reach about $57.8 billion in 2023.

Park Dong-wan, CEO of Neptune Korea, said, "North America, where most of the global companies that currently lead the smart healthcare market are located, has the largest market share. However, the growth rate in Asia is expected to be the highest, where the population of senior citizens, DPI(Disposable Personal Income), and the number of participating companies are expected to increase.

Park has a career in healthcare IT. The technology he developed enhances the effectiveness of healthcare services by detecting and predicting the patient's condition through a variety of information on the patient's behavior and the real-time health status information of the patient.

Neptune Korea has enough competitiveness because smart devices and sensor technology make it easy for people to take "self-health measurements" to record and manage their health conditions, such as their own meals, blood pressure and exercise, and need solutions to the problem of soaring medical costs due to the aging population and increasing number of chronic patients. 

CEO Park said, "We are planning to develop 'patient-customized rehabilitation medical devices' that indicate the effects of shortening the period of rehabilitation treatment or improving safety through the development of sensing, processing, and driving systems using biomedical feedback to enhance the brain plasticity of patients and induce recovery of functions."

"The brain stimulation devices are actively undergoing clinical research in Korea on the treatment effects of stroke as well as depression and cognitive function, which will require the development of standards, safety, and performance evaluation guidelines for related devices."

"The development of standards, safety, and performance evaluation guidelines is required as The brain stimulation devices are actively undergoing domestic clinical research on the treatment effects of depression, cognitive function, and stroke."

“Neptune Korea intends to grow into a non-face-to-face company based on smartphones for early diagnosis of stroke and Parkinson's disease,” Park said.